Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Sep;87(17):6599-603.
doi: 10.1073/pnas.87.17.6599.

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

Affiliations

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

D R Milich et al. Proc Natl Acad Sci U S A. 1990 Sep.

Abstract

Infants born to hepatitis B virus carrier mothers, who express a secreted form of the nucleocapsid antigen designated HBeAg, invariably become persistently infected. To investigate the role of immunologic tolerance mechanisms in chronic infection of the newborn, we have generated HBeAg-expressing transgenic mice. HBeAg-expressing transgenic mice were tolerant to both HBeAg and the nonsecreted nucleocapsid (hepatitis B cor antigen/HBcAg) at the T-cell level. Transgenic mice did not produce antibody to HBeAg but did produce anti-HBc antibody in vivo and in vitro. The coexistence of tolerance to HBc/HBe T-cell determinants and anti-HBc antibody production in vivo parallels the immunologic status of neonates born to carrier mothers. It was also demonstrated that the maintenance of T-cell tolerance to HBcAg/HBeAg required the continued presence of the tolerogen and in its absence persisted for less than 16 weeks. The reversibility of T-cell tolerance to HBcAg/HBeAg may explain the inverse correlation between age of infection and rates of viral persistence. These observations suggest that a function of the HBeAg may be to induce immunologic tolerance in utero. Expression of HBeAg may represent a viral strategy to guarantee persistence after perinatal infection.

PubMed Disclaimer

References

    1. Lancet. 1983 Nov 12;2(8359):1103-4 - PubMed
    1. J Immunol. 1983 Jun;130(6):2903-7 - PubMed
    1. Hepatology. 1986 May-Jun;6(3):369-73 - PubMed
    1. Annu Rev Biochem. 1986;55:913-51 - PubMed
    1. Lancet. 1986 Oct 11;2(8511):872 - PubMed

MeSH terms

LinkOut - more resources